LA JOLLA, Calif., July 17, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, ...
Positive topline results from an interim analysis of the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of farabursen (RGLS8429) for the treatment of autosomal ...
A waxing gibbous moon will occult Regulus after dark on Saturday, April 25, briefly wiping Leo’s brightest star from view for ...
SAN DIEGO, June 27, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
CARLSBAD, Calif., Oct. 11, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that Regulus Therapeutics Inc. recently priced its initial public offering of 11,250,000 ...
LA JOLLA, Calif., July 23, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, ...
VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Regulus Resources Inc. ("Regulus" or the "Company", TSX-V: REG, OTCQX: RGLSF) is pleased to announce that it has executed an agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results